NIPT Tender Award

Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that its wholly owned subsidiary, Yourgene Health UK Ltd ("Yourgene") has been awarded the South West London Procurement Partnership tender for the provision of Non-Invasive Prenatal Testing ("NIPT") using Yourgene's flagship IONA® Nx NIPT Workflow (CE-IVD), for St George's University Hospitals NHS Foundation Trust, London ("St George's") following a competitive tender process.

Yourgene won its first contract with St George's on 23 March 2015 and since then, St George's has been using the IONA® Nx test under the St George's Antenatal Fetal Evaluation ("SAFE") brand. The SAFE test has been set up as a collaboration between the Fetal Medicine Unit and the St George's Genomics Service, which is a UKAS accredited medical laboratory. The service provides NIPT to approximately one third of the NHS (National Health Service) maternity services population in England and is also offered privately at St George's hospital.

The contract is for an initial two-year period from December 2025, with an option to extend for a further two years. This represents a continuation of existing business to the Company.

Yourgene's flagship IONA® Nx NIPT Workflow (CE-IVD) is an in vitro diagnostic device for prenatal screening which enables clinical laboratories to establish their own quality assured non-invasive prenatal screening service for Down's (Trisomy 21), Edwards' (Trisomy 18) and Patau's (Trisomy 13) syndromes, in line with UK National Screening Committee recommendations and NHS England requirements.

Lyn Rees, CEO of Novacyt, commented: "We are very pleased to have been awarded this contract following a competitive tender process and for St. George's continuing confidence in our capabilities. This win underpins the quality of our product and service in a market where we continue to deliver year on year double digit growth. As the sector expands and trade barriers ease, we are well-positioned to capture emerging opportunities and create long-term value. Our focus remains on operational excellence, innovation, and supporting our partners in delivering improved clinical and patient outcomes."